Cargando…
Reply to “Novaferon, treatment in COVID-19 patients”
Autores principales: | Zheng, Fang, Zhou, Yanwen, Zhou, Zhiguo, Ye, Fei, Huang, Baoying, Huang, Yaxiong, Ma, Jing, Zuo, Qi, Tan, Xin, Xie, Jun, Niu, Peihua, Wang, Wenlong, Xu, Yun, Peng, Feng, Zhou, Ning, Cai, Chunlin, Tang, Wei, Xiao, Xinqiang, Li, Yi, Zhou, Zhiguang, Jiang, Yongfang, Xie, Yuanlin, Tan, Wenjie, Gong, Guozhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687364/ https://www.ncbi.nlm.nih.gov/pubmed/33248243 http://dx.doi.org/10.1016/j.ijid.2020.11.179 |
Ejemplares similares
-
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial
por: Zheng, Fang, et al.
Publicado: (2020) -
Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in
Vitro, 2022
por: Ye, Fei, et al.
Publicado: (2022) -
Novaferon, treatment in COVID-19 patients
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021) -
Clinical characteristics of older and younger patients infected with SARS-CoV-2
por: Zhou, Zhiguo, et al.
Publicado: (2020) -
Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivo
por: Li, Meng, et al.
Publicado: (2014)